We report herein a case of bullous pemphigoid(BP) associated with Graves' disease(GD) The patient was 43-year-old female who had suffered frorn GD for 8 years. She had annular, erythematous atrophic plaques with a margin of small vesicles on the frontal and temporal areas, Histopathologic findings of the skin lesion showed subepiderrnal bulla, and numerous eosinophilic infiltrate in the bulla cavity and dermis. Direct immunofluorescent study of perilesional skin revealed linear IgG deposition at the dermo epidermal junction. We think our case shows a higher than chance association of BP and GD because both are basecl on autoimmune mechanism.
Adult ; Dermis ; Eosinophils ; Female ; Graves Disease* ; Humans ; Immunoglobulin G ; Pemphigoid, Bullous* ; Skin

No abstract available.
Ligaments*

No abstract available.
Critical Illness* ; Hemofiltration* ; Humans

Vimentin is an intermediate filament protein normally expressed in mesenchymal cells, but the evidence of the aberrant expression of vimentin in epithelial cancer cells suggests that the vimentin expression might be related to local invasiveness and metastatic potential. There have been a few previous studies on the vimentin expression in human cervical carcinogenesis using in vivo and in vitro models. We examined the immunohistochemical vimentin expression in various squamous epithelial neoplasms of the uterine cervix, including the cervical intraepithelial neoplasia group (n=25), the microinvasive squamous cell carcinoma group (n=15), the invasive squamous cell carcinoma group (n=15) and the metastatic squamous cell carcinoma group (n=8). Vimentin positivity was significantly higher in the invasive than in the intraepithelial group, and in the cases with lymph node metastasis than in those without metastasis, suggesting a relationship between the vimentin expression and progression of the uterine cervical epithelial tumors.
Carcinogenesis ; Carcinoma, Squamous Cell ; Cervical Intraepithelial Neoplasia ; Cervix Uteri* ; Female ; Humans ; Intermediate Filaments ; Lymph Nodes ; Neoplasm Metastasis ; Neoplasms, Glandular and Epithelial* ; Vimentin*

No abstract available.
Esophageal and Gastric Varices*

No abstract available.
Esophageal and Gastric Varices* ; Hypertension, Portal*

No abstract available.
Extracorporeal Circulation* ; Pulmonary Atresia* ; Ventricular Septum*

A clinical review was done on 343 infants and children diagnosed and operated at the Department of Pediatric Surgery in Keimyung University, Dong San Medical Center for congenital gastrointestinal anomalies from January, 1988 to December, 1991. The results are summarized as follows; The most prevalent age group of congenital gastrointestinal anomaly was within first week after birth, and infants within 3months occupied 70% of total, and male to female ratio was 2:1. 2) The moat common lesion of congenital gastrointestinal anomalies was stomach with 87cases (25.4%), followed by anus with 80 cases (23.3%), colon with 63 cases (18.4%) and biliary tract with 38 cases(11.1%). 3) The most common congenital anomaly was congenital hypertophic pyloric stenosis with 87 cases (25.4%), followed by imperforate anus with 70 cases (20.4%), congenital megacolon with 63 cases (18.4%), and prevalent age was 2 week-3month, first week after birth, 1month-3year. 4) The incidence of common congenital gastrointestinal anomalies were mostly higher in male than in female but choledochal cyst was higher in female than in male. 5) Associated anomalies were observed in 14 cases (4%) of total cases, duodenal atresia was seen the highest rate of the associated anomalies and the most common associated anomaly was annular pancreas, followed by Down syndrome, congenital diaphragmatic hernia.
Anal Canal ; Anus, Imperforate ; Biliary Tract ; Child ; Choledochal Cyst ; Colon ; Down Syndrome ; Female ; Hernia, Diaphragmatic ; Hirschsprung Disease ; Humans ; Incidence ; Infant ; Male ; Pancreas ; Parturition ; Pyloric Stenosis ; Stomach

No abstract available.
Heart Septal Defects, Atrial* ; Humans

No abstract available.
Catheters* ; Renal Dialysis*